Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
36 hedge funds and large institutions have $23.3M invested in Lumos Pharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
25% more capital invested
Capital invested by funds: $18.7M → $23.3M (+$4.61M)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
5% less funds holding
Funds holding: 38 → 36 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$250K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 3 |
PAG
Paladin Advisory Group
Clive,
Iowa
|
+$39.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.87M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$72K |
| 3 |
Renaissance Technologies
New York
|
-$48.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$31K |
| 5 |
BlackRock
New York
|
-$18.3K |
LUMO Hedge Fund Activity: Q1 2022 in Review
36 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2022, worth a combined $23.3M — up 25% from $18.7M a quarter earlier.
Fund positioning in LUMO was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Private Advisor Group, opening a new position worth an estimated $250K. The largest seller was NEA Management Company, cutting an estimated $1.87M.
- 36 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2022, down from 38 in Q4 2021.
- Funds reported $23.3M of Lumos Pharma, Inc. Common Stock stock for Q1 2022, up 25% quarter-over-quarter.
- 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2022 was Private Advisor Group, an estimated $250K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2022 was NEA Management Company, an estimated $1.87M sold.
Based on aggregated 13F filings for Q1 2022.